Rixen Stephan
Lehrstuhl für das Recht sozialer Dienstleistungen und Einrichtungen, Institut für Sozialpolitik und Organisation Sozialer Dienste, Universität Kassel.
Z Evid Fortbild Qual Gesundhwes. 2008;102(1):31-6. doi: 10.1016/j.zgesun.2007.12.004.
In Germany orphan (or rare) diseases are not a major issue of healthcare-related social security law. Laws, regulations, courts and the legislature have so far not succeeded in shaping an adequate legal approach. The deficient legal framework seems to correlate to the lack of medical knowledge about orphan diseases. Consequently, equal access to treatment--one of the principles of the German healthcare system--for patients suffering from orphan diseases is not sufficiently assured. Therefore, German legislation is facing the urgent challenge to compensate for the lack of medical knowledge and healthcare resources in this field by defining new rules, by establishing specific health authorities and by reforming the allocation of research efforts. In a way, rare diseases are orphans that attract little public and scientific interest. Provision of an adequate legal framework for the treatment of and research into orphan diseases is likely to promote significant improvements for those affected.
在德国,罕见病并非医疗相关社会保障法的主要议题。到目前为止,法律、法规、法院和立法机构尚未成功制定出适当的法律方法。不完善的法律框架似乎与对罕见病医学知识的缺乏相关。因此,德国医疗体系的原则之一——罕见病患者平等获得治疗的机会——并未得到充分保障。所以,德国立法面临着紧迫挑战,即通过定义新规则、设立特定卫生当局以及改革研究力量的分配,来弥补该领域医学知识和医疗资源的不足。从某种程度上说,罕见病就像无人关注的孤儿,很少引起公众和科学界的兴趣。为罕见病的治疗和研究提供适当的法律框架,可能会给患者带来显著改善。